Inspired by the combination of anti-PD-1 and anti-CTLA4 in lung cancer, the combination of different checkpoint inhibitors (anti-PD-1, anti-NKG2A and anti-TIGIT) was investigated and synergistic anti-tumor effect was observed in preclinical experiments [72]. The gene discussed is PDCD1; the disease is lung carcinoma.